



MAR 19 1999

Sheet 1 of 1

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2026-4230UST

SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)
Jeffrey Schlam et al

FILING DATE

GROUP ACT UNIT
1643

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

HAR	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
HAR	2,253,211	2/9/92	GB	—	—		
HAR	WO 89/06974	8/10/89	WO	—	—		

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

[Signature] *[Signature]* Rotzschke, O. et al, Isolation and analysis of naturally processed viral peptides as recognized by cytotoxic T cells, *Nature* 1990, 348:252-254.

[Signature] *[Signature]* Skipper, J. et al, Identification of Two Cytotoxic T Lymphocyte-recognized Epitopes in the Ras Protein, *The Journal of Experimental Medicine*, 177 (5), 1993, 1493-1498.

EXAMINER

Hans Rafferty Esq.

DATE CONSIDERED

SIDERED 3/21/50 16157a

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through /KAC/

/Karen A. Canella
7/15/2009



MAR 19 1999

Sheet 2 of 1

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2028-4230US1	SERIAL NO. 09/155,590			
INFORMATION DISCLOSURE CITATION						
<i>(Use several sheets if necessary)</i>						
<table border="1"> <tr> <td>APPLICANT(S) Jeffrey Schliom et al</td> <td>FLING DATE September 30, 1998</td> <td>CROSS ART UNIT 1643</td> </tr> </table>				APPLICANT(S) Jeffrey Schliom et al	FLING DATE September 30, 1998	CROSS ART UNIT 1643
APPLICANT(S) Jeffrey Schliom et al	FLING DATE September 30, 1998	CROSS ART UNIT 1643				

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SDBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

<u>JAC</u>	Abrams, S.I. et al, Mutant <i>ras</i> epitopes as targets for cancer vaccines, <u>Sem. Oncol.</u> 23, 118-134 (1996).
<u>HNR</u>	Eishenlohr, L.C. et al, A transient transfection system for identifying biocsynthesized proteins processed and presented to class I MHC restricted T lymphocytes, <u>J. Immunol. Meth.</u> , 1992, 154:131.

EXAMINER

~~Hoplodrina~~ End

DATE CONSIDERED

CONSIDERED 10/5/00
3A2+100

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC/

/Karen A. Garella/ 7/15/2009



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Sheet 3 of 1

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET NO.
2026-4230US1

SERIAL NO.
09/155,590

APPLICANT(S)
Jeffrey Schliom et al

FILING DATE
September 30, 1998

GROUP ART UNIT
1643

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (including Author-Title-Date Pertinent Papers, Etc.)

<i>[Signature]</i>	Peace, D.J. et al, T cell recognition of transforming proteins encoded by mutated <i>ras</i> proto-oncogenes, <i>J. Immunol.</i> , 146, 2059-2065, (1991).
<i>[Signature]</i>	Takahashi, H.S. et al, A single amino acid interchange yields reciprocal CTL specificities for HIV-1 gp 160, <i>Science</i> , 1989, Vol. 246, 118-121.
EXAMINER	<i>Hope Johnson Eustis</i>

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC/

/Karen A. Canella/ 7/15/2009



MAR 19 1999

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Sheet 4 of 1

FORM PTO-1449

ATTY. UCKET NO.
2026-4230US1

SERIAL NO.
09/155,591

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)
Jeffrey Schlom et al

FILING DATE

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Permanent Papers, etc.)

		Rock, K.L. et al, Analysis of the association of peptides of optimal length to class I molecules on the surface of cells, Proc. Natl. Acad. Sci. USA 1992, Vol. 89, 8918-8922.
		Mitsudomi, T. et al, P53 mutation in non small lung cancer cell line and their correlation with the presence of ras mutations and clinical features, Oncogene 1992, Vol. 7, No. 1, 171-180.

EXAMINER

Anne Robinson End

DATE CONSIDERED

DETERRED
~~312-100~~ - 10/5/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

Karen A. Capella, 7/15/2008



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2026-4230US1

SERIAL NO.
09/155,590

Sheet 5 of 17

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

 U. S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2026-4230US1	SERIAL NO. 09/155,590
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>			
APPLICANT(S) Jeffrey Schlom et al			
FILING DATE September 30, 1998		GROUP ART UNIT 1643	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
					YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

<u>HRC</u>	Kahn, S.M. et al, Rapid and sensitive nonradioactive detection of mutant K-ras genes via enriched PCR amplification, <u>Oncogene</u> , Vol. 6, No. 6, 1079-1083 (1991).
<u>HRC</u>	Fenton, R.G. et al, Cytotoxic T-Cell Response and In Vivo Protection Against Tumor Cells
<u>HRC</u>	Harboring Activated ras Proto-oncogenes, <u>Journal of the National Cancer Institute</u> , Vol. 85, No. 16, August 18, 1993.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through /KAC

/Karen A. Canella/ 7/15/2009/



MAR 19 1999

Sheet 6 of 11

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2026-4230US1

SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

APPLICANT(S)
Jeffrey Schlem et al

FILED DATE
September 30, 1998

GROUP A B C D E
1643

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

<u>HK</u>	Tsang, K.Y. et al, Generation of human cytotoxic T cells specific for human carcinoembryonic antigen epitopes from patients immunized with recombinant vaccinia-CEA vaccine, <u>J. Natl. Cancer Inst.</u> , Vol. 87, No. 13, July 1995, 982-990.
<u>HP</u>	Hamer, P.J. et al, Activated Val-12 ras p21 in cell culture fluids and mouse plasma, <u>Oncogene</u> , Vol. 6, No. 9, 1609-1615 (1991).

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through /KAC

/Karen A. Canella/ 7/15/2009/



FORM PTO-1449

MAR 19 1999

Sheet 1 of 17

INFORMATION DISCLOSURE CITATION

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2026-4230US1

SERIAL NO.
09/155,590

APPLICANT(S)
Jeffrey Schlem et al

FILING DATE
September 30, 1998

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

<i>HAC</i>	Carter, G. et al, <i>Ras</i> mutations in patients following cytotoxic therapy for lymphoma, <i>Oncogene</i> , Vol. 5, No. 3, 1990, 411-416.
<i>HAC</i>	Fenton, R.G. et al, Induction of T-Cell Immunity Against <i>Ras</i> Oncoproteins by Soluble Protein or <i>Ras</i> -Expressing <i>Escherichia coli</i> , <i>Journal of the National Cancer Institute (Bethesda)</i> , Vol. 87, No. 24, 1995, 1853-1861.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Capella/ 7/15/2009/



MAR 19 1999

Sheet 8 of 17

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2026-4230US1

SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

APPLICANT(S)

FILED DATE

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

<i>[Signature]</i>	Capon, D. J. et al, Activation of <i>Ki-ras</i> 2 gene in human colon and lung carcinomas by two different point mutations, <u>Nature</u> , Vol. 304, No. 11, August 1983, 507-513.
<i>[Signature]</i>	Bos, J.L., The <i>ras</i> gene family and human carcinogenesis, <u>Mutation Research</u> , 195 (1988), 255-271.

EXAMINER

~~ER~~ Hope Johnson Endt

DATE CONSIDERED

CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through /KAC

/Karen A. Canella/ 7/15/2009/



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2026-4230US1

SERIAL NO.
09/155,5904

Sheet 9 of 11

INFORMATION DISCLOSURE CITATION

APPLICANT(S)
Jeffrey Schlom et al

FILING DATE
September 30, 1996

GROUP ABT ONE
1643

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

<u>H</u>		Van Bleek, G. et al, Isolation of an endogenously processed immunodominant viral peptide from the class I H-2K molecule, <u>Nature</u> 1990, 348:213-216.
<u>H</u>		Mitsudomi, T. et al, Ras gene mutation in non small lung cancer are associated with shortened survival irrespective of treatment intent, <u>Cancer Research</u> 1991, 51:4999-5002.

EXAMINER

survival irrespective of treatment

DATE CONSIDERED

RE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Ganella/ 7/15/2009/



MAR 19 1999

Sheet 10 of 11

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2026-4230US1	SERIAL NO. 09/155,590
INFORMATION DISCLOSURE CITATION				
<i>(Use several sheets if necessary)</i>				
APPLICANT(S) Jeffrey Schlem et al				
FLING DATE September 30, 1996				
GROUP ART UNIT 1643				

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

	Bos, J.L., <i>ras</i> Oncogenes in Human Cancer: A Review, <i>Cancer Research</i> 49, 4682-4689 (1989).
	Fossum, B. et al, CD8+ T cells from a patient with colon carcinoma, specific for a mutant p21-
	<i>Ras</i> -derived peptide (GLY ¹³ >ASP), are cytotoxic towards a carcinoma-cell line harbouring the same mutation, <i>Cancer Immunol. Immunotherapy</i> 40, 165-162 (1995).

EXAMINER

~~ER~~ ~~Hope Patterson Field~~

OATE CONSIDEREO

~~3/21/00~~ 10/5/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through /KAC

/Karen A. Capella/ 7/15/2009/



Sheet 11 of 11

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.
2026-4230US1

SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)
Jeffrey Schlom et al

FILING DATE
September 30, 1996

GROUP ABY UNIT
1643

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

[Signature] Qin, H. et al, CD4+ T-cell immunity to mutated *ras* protein in pancreatic and colorectal cancer patients, Cancer Research 55, 2984-2987 (1995).

[Signature] Abrams, S.I. et al, Peptide-specific activation of cytolytic CD4+ T lymphocytes against tumor cells bearing mutated epitopes of K-*ras* p21, Eur. J. Immunol. 25, 2588-2597 (1995).

EXAMINER

DATE CONSIDERED

~~CONSIDERED~~ 3/24/80 10/5/80

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

Karen A. Canella / 3/15/2008

455932 1



FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2026-4230US1	SERIAL NO. 09/155,5904
INFORMATION DISCLOSURE CITATION				
<i>(Use several sheets if necessary)</i>				
APPLICANT(S) Jeffrey Schlem et al				
FILING DATE September 30, 1996			GROUP ART UNIT 1643	

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Papers, Etc.)

<i>HAR</i>	Abrams, S.I. et al, Identification of overlapping epitopes in mutant <i>ras</i> oncogene peptides that activate CD4+ and CD8+ T cell responses, <i>Eur. Journal of Immunology</i> 26 (2) 1996, 435-443.
<i>HAR</i>	Gjertsen, M.K. et al, <i>Ex vivo ras</i> peptide vaccination in patients with advanced pancreatic cancer: results of a phase I/II study, <i>Int. J. Cancer</i> 65, 450-453 (1996).

EXAMINER

DATE CONSIDERED 10/15/00
Hope Robinson

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through /KAC

Karen A. Canalla: 7/15/2008/



MAR 19 1999

Sheet 13 of 17

FORM PTO-1449

**U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE**

ATTY. DOCKET NO.
2026-4230US1

SERIAL NO.
09/155,590

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

APPLICANT(S)
Jeffrey Schlem et al

FILING DATE
September 30, 1996

**GROOPART 0017
1643**

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

<u>HAC</u>	Van Elsas, A. et al, Induction and characterization of cytotoxic T-lymphocytes recognizing a mutated p21 Ras peptid presented by HLA-A *0201, <u>Int. J. Cancer</u> 61, 389-396 (1995).
<u>HAC</u>	Kiaris, H. et al, Mutations of ras genes in human tumours (review), <u>Int. J. Oncol.</u> 7, 413-421 (1995).

EXAMINER

~~for Richardson~~ Endt

OATE CONSIDERED

~~3/21/00~~ 10/5/00

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/



MAR 19 1999

Sheet 14 of 17

<p>FORM PTO-1449</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i></p>	<p>ATTY. DOCKET NO. 2026-4230US1</p>	<p>SERIAL NO. 09/155,590</p>
<p>APPLICANT(S) Jeffrey Schliom et al</p>		
<p>FILING DATE September 30, 1996</p>		<p>GROUP ART UNIT 1643</p>

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Papers, Etc.)

	Fossum, B. et al, Overlapping epitopes encompassing a point mutation (12 Gly > Arg) in p21
<i>HAC</i>	<i>ras</i> can be recognized by HLA-DR, -DP and -DQ restricted T cells, <i>Eur. J. Immunol.</i> 23, 2687-2691 (1993).
	Geddle-Dahl III et al, T-cell responses against products of oncogenes: generation and
<i>HAC</i>	characterization of human T-cell clones specific for p21 <i>Ras</i> -derived synthetic peptides, <i>Human Immunol.</i> 33, 266-274 (1992).

EXAMINER

~~Hans Eddot~~

DATE CONSIDERED

~~5/21/00~~ 10:58

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

Karen A. Capella / 7/15/2009/

455932 1

FORM PTO-1449		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 2026-4230US1	SERIAL NO. 09/155,590		
INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>							
 <p>MAR 19 1999</p> <p>PATENT & TRADEMARK OFFICE</p>				<p>APPLICANT(S) Jeffrey Schlem et al</p> <p>FILING DATE September 30, 1996</p> <p>GROUP ART UNIT 1643</p>			
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS		
FOREIGN PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)							
<i>HAR</i>	Salter, R.D. et al, Impaired assembly and transport of HLA-A and B antigens in a mutant TxB						
	hybrid, EMBO J., 5, 943-949 (1986).						
<i>HAR</i>	Jung, S. et al, Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras						
	proteins, J. Exp. Med., 163, 273-276 (1991).						
EXAMINER	<i>Hope Robinson Ewald</i>			DATE CONSIDERED			<i>3/21/00 10:51a</i>
EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							
<input type="checkbox"/> All references considered except where lined through. /KAC							
/Karen A. Canella/ 7/15/2009/							

All references considered except where lined through. /KAC

/Karen A. Ganella/ 7/15/2009/

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/

FORM PTO-1449	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 2028-4230US1	SERIAL NO. 09/155,590
INFORMATION DISCLOSURE CITATION			
(Use several sheets if necessary)			
<p style="text-align: center;">OCT 1999 MAR 19 1999 U.S. PATENT & TRADEMARK OFFICE</p>			
APPLICANT(S) Jeffrey Schliom et al		FILING DATE September 30, 1996	GROUP ART UNIT 1643

U.S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Papers, Etc.)

<u>HZ</u>		Gaudernack, G., T cell responses against mutant <i>ras</i> , a basis for novel cancer vaccines Immunotechnology 2 (1996), pp. 3-9.
<u>HZ</u>		Carbone et al, Feasibility of immunization with individualized mutant <i>ras</i> and p53 peptides in patients with solid tumors, Proc. ASCO Vol. 14, p. 546 (6/14/95).

EXAMINER

~~John Robert Eudate~~

DATE CONSIDERED

~~CONSIDERED~~ 321/72 13/5/80

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

All references considered except where lined through. /KAC

/Karen A. Canella/ 7/15/2009/